Medicure Inc. · TSXV:MPH
Medicure — Investor Presentation (May 2025)
15 slides from Medicure's investor presentation, May 22, 2025
Slide 1: Investor Presentation
Medicure Inc. Investor Presentation 2025 SD-MED-AA-01
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-loo
Slide 3: Medicure's 5 Focuses
Medicure’s 5 Focuses Medicure is an R&D specialty pharmaceutical and pharmacy company focused on the US market 1. Growing sales of ZYPITAMAG® 2. Growing sales of Marley Drug® E-Commerce pharmacy subsidiary 3. Maintain sales of AGGRASTAT® 4. Complete Phase 3 Trial of MC-1 for 10 PNPO patients to rece
Slide 4: Medicure's Growth Strategy
Medicure’s Growth Strategy Medicure plans to use its profit to fund R&D and acquisitions Short term: Near term: Long term: Growth of ZYPITAMAG, Build the Marley Drug Development of acquired Marley Drug and maintain business through acquisition new chemical entities for AGGRASTAT and partnerships lar
Slide 5: Medicure's Pharmacy Acquisitions – Why?
Medicure’s Pharmacy Acquisitions – Why? • A more efficient distribution and marketing vehicle for ZYPITAMAG – a branded drug • A profitable marketing vehicle for other branded drugs • Saves on high fees to wholesalers and pharmacy benefit managers • Medicure recently acquired Gateway Medical Pharmac
Slide 6: Key Financial Parameters: Net Revenue
Key Financial Parameters Net Revenue Contributors to Net Revenue $25.0 $25.0 $20.0 $20.0 ZYPITAMAG $15.0 $15.0 $CAD (M) $CAD (M) MARLEY DRUG $10.0 $10.0 AGGRASTAT $5.0 $5.0 $0.0 $0.0 2022 2023 2024 2022 2023 2024 MPH:TSXV 6
Slide 7: Key Financial Parameters: R&D Expenses and Net Cash
Key Financial Parameters R&D Expenses Net Cash Increases $3.5 $1.6 $3.0 $1.4 $1.2 $2.5 $1.0 $CAD (M) $2.0 $0.8 $1.5 $0.6 $1.0 $0.4 $0.5 $0.2 $0.0 $0.0 2022 2023 2024 2022 2023 2024 MPH:TSXV 7
Slide 8: Key Financial Parameters: Net Income
Key Financial Parameters Net Income before Non-Cash Adjustments Net Income (Loss) after Non-Cash Adjustments $4.0 $3.0 $3.5 $2.0 $3.0 $1.0 $2.5 $CAD (M) $2.0 $0.0 $1.5 -$1.0 $1.0 -$2.0 $0.5 $0.0 -$3.0 2022 2023 2024 2022 2023 2024 MPH:TSXV 8
Slide 9: Medicure's Leadership Team
Medicure’s Leadership Team Haaris Uddin Reuben Saba Albert D. Friesen Neil Owens Vice President, Chief Financial Officer Chief Executive Officer & President & Business Development Chairman of the Board Chief Operating Officer • Founded Medicure in • President & COO since • Joined Medicure in 2022 •
Slide 10: ZYPITAMAG
$6.2M INDICATION In 2024 High Cholesterol PRODUCT HIGHLIGHTS • Improvements over older statins 24% • Low rates of side effects like muscle pain from the prior year • Doesn’t interact with other medications • Once daily low dose with strong LDL reduction $ 4B Graphical user interface, website Descrip
Slide 11: Medicure's Pharmacy Subsidiary & E-Commerce Website
Medicure’s Pharmacy Subsidiary & E-Commerce Website WHAT IS MARLEY DRUG $ 10.8M • A US pharmacy subsidiary licensed to ship FDA In 2024 approved medications to all 50 states • Facilitates Medicure selling ZYPITAMAG directly to consumers 12.5% HIGHLIGHTS from the prior year • Increased ZYPITAMAG unit
Slide 12: AGGRASTAT
INDICATION Acute Coronary Syndrome $8.1M PRODUCT HIGHLIGHTS • Leading IV antiplatelet in its class In 2024 • Medicure grew market share from 2% to 65% • Used in more than 1,000 hospitals • Three formats of the product available Graphical user interface, website Description automatically generated MP
Slide 13: Development of MC-1 for Rare Pediatric Disease
PHASE 3 CLINICAL STUDY Development of MC-1 for Rare Pediatric Disease Phase 3 study for treatment of rare pediatric disease called PNPO deficiency • Study involves 10-15 patients in US and Australia • Orphan Drug Status and Fast Track Designation • Study is ongoing • If approved Medicure is eligible
Slide 14: Development of New Chemical Entities
R&D PIPELINE Development of New Chemical Entities Medicure acquired intellectual property related to analogues of pyridoxal 5’-phosphate • Significant advantages over existing compounds • Clinical targets have not yet been disclosed • Targeting large unmet therapeutic needs • Currently in pre-clinic
Slide 15: Thank You for Your Interest
Thank You for Your Interest For Further Information Visit our Websites Investor Relations Medicure.com [email protected] AGGRASTAT.com 1-888-435-2220 (Ext. 228) ZYPITAMAG.com Marley Drug.com Follow us on LinkedIn MPH:TSXV 15